Medtronic’s extravascular defibrillator receives CE mark

Manufacturing & Production

Medtronic has received the CE mark for its extravascular defibrillator. The Aurora EV-ICD™ MRI SureScan™ and Epsila EV™ MRI SureScan™ defibrillation lead treat abnormally fast heart rhythms, which can lead to sudden cardiac arrest.

Implantable cardioverter-defibrillators (ICDs) are a highly effective treatment for sudden cardiac arrest (SCA). They detect when the patient is experiencing an abnormally fast heart rate and deliver therapy to terminate a potentially fatal arrhythmia.

The Aurora EV-ICD system offers the same defibrillation, anti-tachycardia pacing (ATP) and back-up pacing therapies as traditional ICDs, however its thin wire is placed outside of the heart and veins. Traditional transvenous ICDs are implanted in the chest and attached to leads, which are threaded through veins into the heart. Aurora EV-ICD is implanted below the left armpit, with the Epsila EV lead being placed under the sternum, avoiding any intrusion into the veins and heart. This avoids certain long-term risks such as vessel occlusion and blood infections.

Aurora EV-ICD received its CE mark after the Extravascular Implantable Cardioverter Defibrillator (EV ICD) Pivotal Study met its safety and effectiveness endpoints.

Alan Cheng, MD, chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic stated, “We are proud to be the first company to offer a complete one-system, one-procedure extravascular ICD solution, which maintains the patient benefits of traditional, transvenous ICDs without the risk of leads in the heart and vasculature. This approval is a significant milestone in achieving our goal of delivering a defibrillation solution that treats sudden cardiac arrest while improving the patient experience.”

Moderna chooses Oxfordshire for new UK facility

US biotech firm Moderna has chosen Harwell Science Campus in Oxfordshire for its new UK R&D facility. The campus is already home to more than 70 organisations and sits within the UK’s ‘golden triangle’, an area rich in life sciences facilities, between Oxford, Cambridge and London.

REGENXBIO presents interim phase 2 data from drug developed on NAVXpress platform

REGENXBIO, a clinical-stage biotech company, has announced positive phase 2 data for its drug rxg-314, which was developed by the company’s NAVXpress bioreactor platform process.

Johnson & Johnson Scale Back COVID-19 Vaccination Production

J&J has begun scaling back its COVID-19 vaccine producation due to the falling demand for the jabs

Eli Lilly Plans To Invest $450m At Production Site In Research Triangle Park

Eli Lilly has announced plans to invest $450m in manufacturing facilities at Research Triangle Park in North Carolina, US

Daiichi Sankyo To Build Japan’s First Factory For mRNA COVID-19 Vaccines

Daiichi Sankyo shares plans to build its first mRNA COVID-19 vaccine factory in Japan

Moderna chooses Oxfordshire for new UK facility

REGENXBIO presents interim phase 2 data from drug developed on NAVXpress platform

Johnson & Johnson Scale Back COVID-19 Vaccination Production

Eli Lilly Plans To Invest $450m At Production Site In Research Triangle Park

Daiichi Sankyo To Build Japan’s First Factory For mRNA COVID-19 Vaccines

Pharmafocus

Categories

Social Footprints